Understanding the Molecular Pathways of Inflammatory Cytokines in Neurodegenerative Disorders

Beneto Revert^*
*Correspondence: Beneto Revert, Department of Clinical Neurosciences, Vita–Salute San Raffaele University, Milan, Italy, Italy, Email:

Introduction

Neurodegenerative disorders, including Alzheimer's Disease (AD), Parkinson's Disease (PD), Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS), are progressive conditions characterized by the degeneration of neurons, leading to cognitive, motor, and functional impairments. While the precise causes of these diseases remain unclear, increasing evidence suggests that neuroinflammation-driven by the activation of inflammatory cytokines-plays a critical role in the progression of neurodegenerative diseases. Cytokines, which are small signaling proteins produced by immune cells, have long been known to regulate immune responses and inflammation. However, in the context of neurodegenerative diseases, the activation of these cytokines within the Central Nervous System (CNS) can exacerbate neuronal damage, contributing to disease progression. This article aims to explore the molecular pathways of inflammatory cytokines in neurodegenerative disorders, examining their roles in disease pathogenesis, and highlighting potential therapeutic strategies to target these pathways in the management of these debilitating diseases [1].

Description

Inflammatory cytokines are crucial mediators in the immune response, but their dysregulation within the brain can lead to harmful effects on neuronal survival and function. In neurodegenerative diseases, both peripheral immune cells (e.g., macrophages and T cells) and resident CNS cells (e.g., microglia and astrocytes) can produce pro-inflammatory cytokines, triggering a cascade of immune responses. These cytokines, including Tumor Necrosis Factor-Alpha (TNF-α), Interleukins (IL-1β, IL-6, IL-17), Interferons (IFN-γ), and Transforming Growth Factor-Beta (TGF-β), have been implicated in the progression of neurodegenerative diseases.

Understanding how these inflammatory cytokines contribute to neurodegeneration requires examining the specific molecular pathways involved in their signaling. Cytokines act by binding to their corresponding receptors on target cells, which activates intracellular signaling cascades that regulate gene expression and cellular responses. In the context of neurodegenerative diseases, cytokines activate pathways that increase inflammation, promote neurotoxic responses, and impair neuronal function. TNF-α is a potent pro-inflammatory cytokine that is often upregulated in neurodegenerative diseases such as Alzheimer's and Parkinson's disease. TNF-α signaling occurs primarily through two receptors, TNFR1 and TNFR2, triggering the activation of various intracellular pathways, including the NF- κB (nuclear factor-kappa B) pathway. The NF-κB pathway promotes the transcription of genes involved in inflammation, cell survival, and apoptosis. In neurodegenerative diseases, chronic TNF-α signaling contributes to neuronal death and glial activation, exacerbating the neuroinflammatory environment [2].

IL-1�� is another major pro-inflammatory cytokine involved in neurodegeneration. IL-1β is produced as an inactive precursor (pro-IL-1β) and is activated by the inflammasome, a multiprotein complex that responds to cellular stress. Once activated, IL-1β binds to the IL-1 Receptor (IL-1R) and triggers the activation of several signaling pathways, including the NF- κB and MAPK (mitogen-activated protein kinase) pathways. These pathways lead to the production of more inflammatory cytokines and chemokines, which drive neuroinflammation and neuronal injury. Elevated IL-1β levels have been observed in the brains of patients with Alzheimer's disease, Parkinson's disease, and MS. IL-6 is a pleiotropic cytokine that regulates immune responses and inflammatory processes. In neurodegenerative diseases, IL-6 is produced by both glial cells and neurons, and its signaling contributes to neuroinflammation, synaptic dysfunction, and neuronal death. IL-6 signals through the JAK-STAT (Janus kinase-signal transducer and activator of transcription) pathway, which activates transcription factors like STAT3 [3]. In the brain, chronic activation of IL-6 signaling has been linked to the progression of Alzheimer's and Parkinson's disease, as IL-6 promotes the release of amyloid-beta plaques and induces oxidative stress.

IL-17 is produced by Th17 cells and plays a critical role in autoimmunemediated neuroinflammation, particularly in multiple sclerosis. IL-17 signaling activates the NF-κB and MAPK pathways, promoting the production of proinflammatory cytokines and chemokines. This leads to the recruitment of immune cells into the CNS and exacerbates neuroinflammation. Elevated levels of IL-17 have been found in the Cerebrospinal Fluid (CSF) of MS patients and are associated with increased disease activity. TGF-β is a cytokine with dual roles in neurodegenerative diseases. While it has anti-inflammatory properties under normal conditions, its dysregulation can contribute to disease progression. In diseases like Alzheimer's and ALS, TGF-β signaling can exacerbate glial activation and fibrosis, leading to neurodegeneration. TGF-β signals through the Smad pathway, which regulates the expression of genes involved in cell survival and fibrosis. Inappropriate activation of TGF-β can disrupt the balance between neuroprotective and neurotoxic responses, ultimately promoting neuronal injury.

The molecular pathways of inflammatory cytokines not only drive inflammation but also have direct toxic effects on neurons. Chronic inflammation in the brain leads to the activation of microglia, the resident immune cells of the CNS, which release additional pro-inflammatory cytokines and Reactive Oxygen Species (ROS). These molecules contribute to oxidative stress, mitochondrial dysfunction, and the breakdown of the Blood- Brain Barrier (BBB), allowing peripheral immune cells to infiltrate the brain and exacerbate the inflammatory environment. Furthermore, inflammatory cytokines can disrupt neuronal function by impairing synaptic plasticity and neurotransmitter release. For example, IL-1β has been shown to alter synaptic transmission and impair Long-Term Potentiation (LTP), a process essential for memory and learning. The sustained activation of glial cells and the release of cytokines can also promote the accumulation of misfolded proteins, such as amyloid-beta and tau in Alzheimer's disease, or alpha-synuclein in Parkinson's disease, which are key features of these diseases [4]. Inhibitors of specific cytokines, such as TNF-α blockers (e.g., infliximab) or IL-1β inhibitors (e.g., anakinra), have shown potential in preclinical models of neurodegeneration. Clinical trials are ongoing to assess the efficacy of these therapies in diseases like Alzheimer's and Parkinson's disease. JAK inhibitors, such as tofacitinib, which target IL-6 signaling, are being investigated for their potential to reduce neuroinflammation and improve disease outcomes in neurodegenerative conditions. Early studies suggest that these inhibitors may help control chronic inflammation and slow disease progression. Drugs such as fingolimod, used in MS, act on the immune system to modulate T-cell responses and reduce the infiltration of immune cells into the CNS. These drugs may also help regulate the release of inflammatory cytokines within the brain.

Emerging evidence suggests that the gut microbiome influences neuroinflammation. Modulating the gut microbiota through probiotics, prebiotics, or dietary interventions may provide an indirect means of regulating inflammatory cytokines and improving neurodegenerative outcomes. While cytokine-targeted therapies hold promise, several challenges remain. The Blood-Brain Barrier (BBB) is a major obstacle in delivering cytokine inhibitors to the brain. Additionally, the complex interplay between neuroinflammation and neurodegeneration makes it difficult to determine the optimal timing and dosage of treatments. Furthermore, cytokine inhibitors can have off-target effects and may impair the body's ability to mount an immune response to infections. Future research will need to focus on developing more specific and efficient strategies for targeting inflammatory cytokines within the CNS, such as nanoparticle-based delivery systems or gene therapy. Additionally, biomarkers that accurately reflect cytokine-driven neuroinflammation will be critical in guiding treatment decisions and monitoring disease progression [5].

Conclsuion

Inflammatory cytokines play a pivotal role in the pathogenesis of neurodegenerative diseases by driving neuroinflammation, promoting neuronal damage, and contributing to disease progression. Understanding the molecular pathways of these cytokines, including TNF-α, IL-1β, IL-6, and IL- 17, is essential for developing targeted therapies to manage and potentially halt the progression of these debilitating diseases. While current therapeutic strategies hold promise, overcoming challenges such as BBB penetration, specificity, and off-target effects will be crucial for the future development of more effective treatments. As research continues to unravel the complex interactions between inflammatory cytokines and neurodegeneration, the hope for more precise and personalized therapies grows stronger.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Nabi, Masarat and Nahida Tabassum. "Role of environmental toxicants on neurodegenerative disorders." Front Toxicol 4 (2022): 837579.

 Google Scholar, Crossref, Indexed at

2. Chen, Xueping, Chunyan Guo and Jiming Kong. "Oxidative stress in neurodegenerative diseases." Neural Regen Res 7 (2012): 376-385.

 Google Scholar, Indexed at

3. Guzman-Martinez, Leonardo, Ricardo B. Maccioni, Víctor Andrade and Leonardo Patricio Navarrete, et al. "Neuroinflammation as a common feature of neurodegenerative disorders." Front Pharmacol 10 (2019): 1008.

 Google Scholar, Crossref, Indexed at

4. Popa-Wagner, Aurel, Dinu Iuliu Dumitrascu, Bogdan Capitanescu and Eugen Bogdan Petcu, et al. "Dietary habits, lifestyle factors and neurodegenerative diseases." Neural Regen Res 15 (2020): 394-400.

Google Scholar, Crossref, Indexed at

5. Poulose, Shibu M., Marshall G. Miller, Tammy Scott and Barbara Shukitt-Hale. "Nutritional factors affecting adult neurogenesis and cognitive function." Adv Nutr 8 (2017): 804-811.

Google Scholar, Crossref, Indexed at